Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases.
about
P1343
The urgent need to recover MHC class I in cancers for effective immunotherapyDatabase of T cell-defined human tumor antigens: the 2013 updateTherapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1.Serum reactome induced by Bordetella pertussis infection and Pertussis vaccines: qualitative differences in serum antibody recognition patterns revealed by peptide microarray analysis.Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients.Tumor mouse model confirms MAGE-A3 cancer immunotherapeutic as an efficient inducer of long-lasting anti-tumoral responses.Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer TreatmentIntramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions.Generation of more effective cancer vaccinesIdentification of immunogenic LY6K long peptide encompassing both CD4(+) and CD8(+) T-cell epitopes and eliciting CD4(+) T-cell immunity in patients with malignant diseaseGenomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity.Epidermal growth factor receptor and variant III targeted immunotherapy.Adoptive transfer of siRNA Cblb-silenced CD8+ T lymphocytes augments tumor vaccine efficacy in a B16 melanoma modelCheckpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.A pilot Phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanoma.A therapeutic microparticle-based tumor lysate vaccine reduces spontaneous metastases in murine breast cancer.Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses.Genetic vaccines to potentiate the effective CD103+ dendritic cell-mediated cross-priming of antitumor immunity.Tumor-Associated Glycans and Immune SurveillanceTIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients.Evaluation of antigen specific recognition and cell mediated cytotoxicity by a modified lysispot assay in a rat colon carcinoma modelAntigen spreading-induced CD8+T cells confer protection against the lethal challenge of wild-type malignant mesothelioma by eliminating myeloid-derived suppressor cells.The determinants of tumour immunogenicity.Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.Immune correlates of melanoma survival in adoptive cell therapy.Multiple vaccinations: friend or foe.Cancer immunotherapy targeting neoantigens.Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccinesNegative influence of programmed death-1-ligands on the survival of esophageal cancer patients treated with chemotherapySecreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo.EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss.AIRE polymorphism, melanoma antigen-specific T cell immunity, and susceptibility to melanoma.MAGE-A Antigens and Cancer Immunotherapy.Sindbis viral vectors transiently deliver tumor-associated antigens to lymph nodes and elicit diversified antitumor CD8+ T-cell immunity.Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?Adoptive transfer with high-affinity TCR to treat human solid tumors: how to improve the feasibility?Cytotoxic chemotherapy and CD4+ effector T cells: an emerging alliance for durable antitumor effects.T cell immunotherapy for melanoma from bedside to bench to barn and back: how conceptual advances in experimental mouse models can be translated into clinical benefit for patients.HLA-binding properties of tumor neoepitopes in humans.Moving receptor redirected adoptive cell therapy toward fine tuning of antitumor responses.
P2860
Q26770165-E0D7CD47-F7B1-4488-94DE-E9CA49E3D21EQ27022422-F34CCE3F-6C05-4486-B710-22FE5B9E15B0Q27313856-332A24B5-AFD7-40CB-861A-11859A935D4AQ30656264-9F6F20C8-57C2-4854-AF02-B3D7F794B910Q30846001-2F9DFC4E-78E5-47A7-AD4F-BC7A69AD16ECQ33617905-9610EA29-5DDD-4830-A366-E5436CCB5D5FQ33718182-C1AEDD4B-EEF3-453B-BFC5-04ED3C520840Q33862762-F2D0C4EF-87D7-45D5-97A6-CD4E6940011BQ34169981-4F481BF5-58A7-4CE2-A5C2-AC57959AE736Q34372937-F5C09AEF-C310-469D-A7D4-AE87A1258B3DQ34375163-62BB5C1E-5A82-460B-BA74-19E881F2D526Q34391942-D4AFD8D4-611B-44B2-A06F-CFA3185DE2F2Q34409836-47F45A7C-F531-4DDA-9A59-A817CB178288Q34788858-277990CD-959A-446A-BB34-817697F4BEAFQ35201915-6C8100DE-A682-4727-8BE8-A173D83530BFQ35318315-8D3A7745-ABA4-4B23-9515-AE0FDF28ABA2Q35569528-4E5341DC-F622-4638-BC9C-C43515643ADAQ35691240-7DA251E0-D136-4807-81A9-278DB9A4067CQ35890610-91F36B14-E051-4CA5-AAED-43A039CEC8E3Q36057454-8661EDCC-CC53-41A5-936F-11AF4EA6511CQ36092291-69B97A74-216E-403F-A453-8A07C025C210Q36544867-6B0E5DB2-7C38-40FF-9564-2D67897E562FQ36555524-384B7057-7D50-4E27-9E96-245A67D9E92CQ36637039-C9589C8C-A03C-4D4D-84AC-A45800EEE89AQ36694896-4108D274-2274-43BD-9ED2-3DA45C6D7407Q36734688-27648670-BF6F-4466-9D99-5A3F2044B553Q36889067-366359AA-AA88-483C-8917-D2021612B940Q37137360-76CE4533-5A3F-4671-A80F-D73E70E289F0Q37142435-A43F80F5-32C3-43DB-876E-323E933E4895Q37240065-52C81DB6-465E-4E09-A35F-A66DC3324CF1Q37618652-36373D8A-E76C-4F31-AF6A-E4FCDE761B9CQ37641531-CBE0E769-A388-4608-A975-65D719AA5EC0Q37685379-6088EB2B-98E4-4A94-A37C-3248B2D0CBF7Q37690452-0AB82B75-246D-444E-B25B-AD1891FB50B3Q37873379-2CD39A72-50A1-4133-995D-D3A9B11CB820Q37986559-B405059D-353E-4DFB-B522-627756A4C9B5Q37991701-1BD8AD39-FA1B-41DA-A65A-779BBAB091E3Q38101679-AB7739A6-5DAC-4E8E-AD9E-87FA8BDED56DQ38217357-AC29A0A5-45EB-4F5A-BA33-75B223EC9D95Q38218786-D3612E1A-12C1-4AD7-9A98-0B8B234C2BD3
P2860
Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Antigen spreading contributes ...... ession of melanoma metastases.
@ast
Antigen spreading contributes ...... ession of melanoma metastases.
@en
type
label
Antigen spreading contributes ...... ession of melanoma metastases.
@ast
Antigen spreading contributes ...... ession of melanoma metastases.
@en
prefLabel
Antigen spreading contributes ...... ession of melanoma metastases.
@ast
Antigen spreading contributes ...... ession of melanoma metastases.
@en
P2093
P1433
P1476
Antigen spreading contributes ...... ession of melanoma metastases.
@en
P2093
Benoît J Van den Eynde
Bernard Lethé
Christophe Lurquin
Jacques Chapiro
Nicolas van Baren
Pierre G Coulie
Thierry Boon
Vincent Stroobant
Véronique Corbière
P304
P356
10.1158/0008-5472.CAN-10-2693
P407
P577
2011-01-07T00:00:00Z